Skip to main content
SIU 2026 Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench to Bedside
Bench to Bedside
SIU@U
SIU@U
    Session Type: Bench-to-Bedside

    8th Bench-to-bedside Uro-Oncology: GU Cancers Triad Meeting - BLADDER CANCER

    Friday, November 13, 2026
    10:00 - 11:50 CET

    Bench to Bedside SIU@U

      Moderator(s)

    • Peter Black

      Professor
      University of British Columbia, Canada

    The rapidly evolving landscape of GU cancers presents significant challenges for specialists across urology, medical oncology, and radiation oncology. As new data emerge, clinicians are required to stay current with the latest developments to ensure the highest standard of care for their patients.

    Join the prestigious B2B Scientific Programme Committee and global thought leaders to stay current with the latest advances and evidence-based practices in GU cancers. In this all-day programme, the multidisciplinary faculty will review updates on diagnosis and treatment of prostate, bladder, and kidney cancers, discuss applications of new therapeutic strategies and surgical skills into clinical practice, and provide guidance for improving patient-centered care.

    Learning Objectives:

    At the end of this session, attendees should be able to:
    • Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
    • Recognize the role of imaging and genetic markers in guiding treatment decision-making.
    • Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
    • Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
    • Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

    Presentations:

    • 10:00 - 10:05 CET
      Welcome and Introductions

      Co-Chair: Peter Black – University of British Columbia

      Co-Chair: Simon Tanguay – McGill University

    • 10:05 - 10:20 CET
      First-Line Therapy for High-Risk NMIBC
    • 10:20 - 10:50 CET
      Case-Based Discussion: Intravesical Therapy Selection for BCG-unresponsive NMIBC

      Moderator: Peter Black – University of British Columbia

      Panelist: Kilian Martin Gust – Austria

    • 10:50 - 11:05 CET
      Novel PET Imaging and Theranostics in Bladder Cancer

      Speaker: Kilian Martin Gust – Austria

    • 11:05 - 11:35 CET
      Case-Based Discussion: Perioperative Systemic Therapy for MIBC

      Moderator: Kilian Martin Gust – Austria

      Panelist: Peter Black – University of British Columbia

    • 11:35 - 11:50 CET
      Treatment Sequencing in Advanced Bladder Cancer After Enfortumab Vedotin and Pembrolizumab